Richard S. Levy - 01 Feb 2026 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
Director
Signature
/s/ Douglas Barry, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Feb 2026
Net transactions value
$0
Form type
4
Filing time
04 Feb 2026, 18:20:58 UTC
Previous filing
26 Jan 2026
Next filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levy Richard S Director C/O KINIKSA PHARMACEUTICALS INT'L, PLC, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM /s/ Douglas Barry, Attorney-in-Fact 04 Feb 2026 0001454983

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +683 +3.7% 19,157 01 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +683 $0.000000 683 01 Feb 2026 Class A Ordinary Shares 683 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -683 -100% $0.000000 0 01 Feb 2026 Class A Ordinary Shares 683 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vested immediately upon grant on February 1, 2026; there was no expiration date for the RSUs.